中文

Genmab (GMAB)

Biotech

Close on Nov 12, 2026 (from our latest Long View update): $51.74

Market value
$31.8Bat the Nov 12 close
Revenue growth
+19%FY2025 (20-F)
FCF margin
30%FY2025 (20-F)
Net debt
$3.6Bat Dec 31, 2025
Worst fall since listing
−84.2%Jun 2, 2009 to Aug 8, 2011; back to that high in Sep 2013

About the company

Latest

  • Up 28.3% Move
    Genmab jumps 28% as its head and neck cancer drug halves the risk of death

The Long View

For most of its history Genmab has lived on royalties from drugs it discovered and licensed out, chiefly Darzalex.

Self-funding

▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash

Updated Nov 12, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

More of our coverage that names Genmab

Long-term fundamentals

Annual results for Genmab, FY2021–FY2025, as reported in its 20-F annual reports.

Revenue and free cash flow

Revenue went from $1.3B in FY2021 to $3.7B in FY2025. Free cash flow was positive in 5 of the 5 years shown; FY2025: $1.1B. Each year's figures are in the table below. $0$1B$2B$3B$4B ’21 ’22 ’23 ’24 ’25

Revenue went from $1.3B in FY2021 to $3.7B in FY2025.

Free cash flow was positive in 5 of the 5 years shown; FY2025: $1.1B.

Margins

Operating margin was 29% in FY2025, vs 35% in FY2021. Gross margin was 94% in FY2025, vs 100% in FY2021. Each year's figures are in the table below. 0%25%50%75%100% ’21’22’23’24’25

Operating margin was 29% in FY2025, vs 35% in FY2021.

Gross margin was 94% in FY2025, vs 100% in FY2021.

Diluted share count

The diluted share count fell 5% from FY2023 to FY2025, to 63M. Each year's figures are in the table below. 62M63M64M65M66M ’23’24’25

The diluted share count fell 5% from FY2023 to FY2025, to 63M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$3.7B94%29%$963M$1.2B$55M$1.1B
FY2024$3.1B95%31%$1.1B$1.1B$44M$1.1B
FY2023$2.4B99%32%$631M$1.1B$54M$1.0B
FY2022$2.0B100%43%$750M$555M$45M$510M
FY2021$1.3B100%35%$470M$354M$40M$314M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202563M$1.7B$5.3B$128M—$430M
FY202465M$3.0B$0$105M—$560M
FY202366M$4.2B$0$85M—$81M
FY2022—$3.2B$0———
FY2021—$3.1B$0———

Source: company 20-F annual reports via SEC EDGAR (XBRL data); fiscal years. Data fetched Oct 30, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 20-F data.

  • Genmab files annual reports on Form 20-F (IFRS). US dollars have been its presentation currency since Jan 1, 2025; FY2021–FY2025 come from the 2025 annual report's key figures (Exhibit 15.3 to the 20-F), which restate earlier years in US dollars. Years before 2021 (Danish kroner) are not shown, so the series stays in one currency. Cash includes marketable securities. Capital spending includes investments in intangible assets, as in Genmab's own key figures. Under IFRS, interest paid is in operating cash flow and lease payments are financing cash flows, so free cash flow here does not deduct lease payments. One American depositary share (ADS) represents one-tenth of an ordinary share.
  • Gross profit is revenue minus cost of revenue (the 20-F does not report a gross profit line).
  • Reviewed figures: Genmab 2025 annual report, Key Figures (USD millions), Exhibit 15.3 to the 20-F filed Feb 17, 2026.

Returns by year

YearGMABS&P 500
2019+35.5%+31.5%
2020+82.1%+18.4%
2021−2.7%+28.7%
2022+7.1%−18.1%
2023−24.9%+26.3%
2024−34.4%+25.0%
2025+47.6%+17.9%
2026 to date+66.7%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Genmab

How does Genmab make money?
Mostly from royalties on antibody drugs it invented and licensed to larger companies, above all Johnson & Johnson's multiple myeloma drug Darzalex. It also sells two medicines of its own with partners: EPKINLY for lymphoma, with AbbVie, and Tivdak for cervical cancer, with Pfizer. More in the Long View →
What happens to Genmab when Darzalex royalties fall?
Genmab expects its Darzalex royalties, its biggest source of income, to begin to decline materially in 2029, when its US patent rights expire. It is building its own medicines to replace them, including two drugs it acquired: Rina-S and petosemtamab. More in the Long View →
Does Genmab have debt?
Yes, since December 2025, when it borrowed $5.5 billion in term loans and notes to help pay for Merus. The final maturities fall between 2030 and 2033, with loan instalments due earlier; the Term A loan and the revolving credit facility carry financial covenants tested each quarter. More in the Long View →
Who are Genmab's main partners?
Johnson & Johnson, which sells Darzalex and other drugs built on Genmab technology and pays most of Genmab's revenue; Novartis, through Kesimpta royalties; AbbVie, its partner on EPKINLY; and Pfizer, its partner on Tivdak. More in the Long View →
What's coming up for Genmab's pipeline in the next 12 months?
Genmab says its October Phase 3 readouts for epcoritamab, Rina-S and petosemtamab support multiple regulatory submissions and potential launches in 2027, and it expects to launch petosemtamab in 2027, subject to results and approvals. Full results are to be presented at medical meetings; no filing dates have been given. As of Nov 12, 2026 More in the Long View →